BioXcel Therapeutics, Inc.
https://www.bioxceltherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioXcel Therapeutics, Inc.
Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence